NCT01317420View on ClinicalTrials.gov

Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 13, 2011

Primary Completion Date

February 15, 2016

Study Completion Date

February 15, 2016

Conditions
Neoplasms
Interventions
DRUG

BI 836845

Intravenous infusion

Trial Locations (2)

LS9 7TF

St James's University Hospital, Leeds

SM2 5PT

The Royal Marsden Hospital, Sutton, Sutton

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01317420 - Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types | Biotech Hunter | Biotech Hunter